Young Therapeutics LLC has the rights to five PKC modulating compounds that attenuate myocardial ischemia-reperfusion (MI/R) injury the technology is patent protected. Of these five, a PKC epsilon peptide inhibitor (YT-001) was the most effective in restoring post-reperfused cardiac function and attenuating neutrophil infiltration in a rat MI/R model. YT-001 is effective in restoring post-reperfused heart function..